Delving into the Latest Updates on Tilidine Hydrochloride/Naloxone with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

复方盐酸替利定, 盐酸替利定/纳洛酮

Target

Opioid receptors x μ opioid receptor

Action

agonists, antagonists

Mechanism

Opioid receptors agonists(Opioid receptors agonists), μ opioid receptor antagonists(Mu opioid receptor antagonists)

Therapeutic Areas

Nervous System DiseasesSkin and Musculoskeletal DiseasesOther Diseases

Active Indication

Cancer PainAcute PainArthralgia+ [5]

Inactive Indication-

Originator Organization

Hebei Aoxing Group Pharmaceutical Co. Ltd.

Active Organization

Hebei Aoxing Group Pharmaceutical Co. Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC17H24ClNO2

InChIKeyMUWDJVKYGSDUSH-KALLACGZSA-N

CAS Registry27107-79-5

View All Structures (2)

According to relevant requirements, the pharmacokinetic study of multiple-dose oral administration of compound tilidine hydrochloride capsules developed by Hebei Aoxing Group Pharmaceutical Co., Ltd. in vivo was conducted in patients with cancer pain. The research content included pharmacokinetic study of multiple-dose administration, safety evaluation and efficacy evaluation.

Start Date02 Aug 2013

Sponsor / Collaborator

Hebei Aoxing Group Pharmaceutical Co. Ltd.

CTR20130620

/ RecruitingPhase 1

采用无对照开放、单剂量顺序给药的研究方法评价复方盐酸替利定口服溶液的药代动力学特性

[Translation] Evaluation of the pharmacokinetic properties of compound tilidine hydrochloride oral solution by an uncontrolled open-label, single-dose sequential administration study

本试验的目的是评价四川抗菌素工业研究所有限公司和国药集团工业有限公司廊坊分公司共同研制的复方盐酸替利定口服溶液人体药代动力学特性及安全性，为临床安全、合理用药提供参考依据。

[Translation]

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety of the compound tilidine hydrochloride oral solution jointly developed by Sichuan Antibiotics Industrial Research Institute Co., Ltd. and Sinopharm Group Industrial Co., Ltd. Langfang Branch in humans, and to provide a reference for safe and rational clinical use of drugs.

Start Date09 Mar 2013

Sponsor / Collaborator

Sichuan Antimicrobial Industry Research Institute

[+1]

100 Clinical Results associated with Tilidine Hydrochloride/Naloxone

Login to view more data

100 Translational Medicine associated with Tilidine Hydrochloride/Naloxone

Login to view more data

100 Patents (Medical) associated with Tilidine Hydrochloride/Naloxone

Login to view more data

100 Deals associated with Tilidine Hydrochloride/Naloxone

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cancer Pain	Phase 2	China	Hebei Aoxing Group Pharmaceutical Co. Ltd.	12 Aug 2013
Acute Pain	Phase 2	China	Hebei Aoxing Group Pharmaceutical Co. Ltd.	28 Mar 2011
Arthralgia	Phase 2	China	Hebei Aoxing Group Pharmaceutical Co. Ltd.	28 Mar 2011
Chronic Pain	Phase 2	China	Hebei Aoxing Group Pharmaceutical Co. Ltd.	28 Mar 2011
Moderate pain	Phase 2	China	Hebei Aoxing Group Pharmaceutical Co. Ltd.	28 Mar 2011
Neuralgia	Phase 2	China	Hebei Aoxing Group Pharmaceutical Co. Ltd.	28 Mar 2011
Post-traumatic pain	Phase 2	China	Hebei Aoxing Group Pharmaceutical Co. Ltd.	28 Mar 2011
Severe pain	Phase 2	China	Hebei Aoxing Group Pharmaceutical Co. Ltd.	28 Mar 2011